SCM
SIOX

Sterling Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Sterling Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,553
Closed -$85K – 980
2017
Q3 		$85K Buy
+1,553
New +$262K ﹤0.01% 905
2015
Q3 		– Sell
-2,500
Closed -$408K – 1041
2015
Q2 		$408K Buy
+2,500
New +$424K ﹤0.01% 752

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sterling Capital Management's SIOX Position: Q4 2017 in Review

Sterling Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 1,553 shares — an estimated $85K sold.

Sterling Capital Management first reported a position in SIOX in Q2 2015 and held it in 2 quarters. The position peaked at $408K in Q2 2015. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • Sterling Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Sterling Capital Management sold 1,553 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $85K.
  • Sterling Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Sterling Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $408K in Q2 2015.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Sterling Capital Management's 13F filing for Q4 2017, filed 15 Feb 2018.